Muscle Uncoupling Protein 3 Expression Is Unchanged by Chronic Ephedrine/Caffeine Treatment: Results of a Double Blind, Randomised Clinical Trial in Morbidly Obese Females
Ephedrine/caffeine combination (EC) has been shown to induce a small-to-moderate weight loss in obese patients. Several mechanisms have been proposed, among which an increased thermogenic capacity of skeletal muscle consequent to the EC-induced up-regulation of uncoupling protein 3 (UCP3) gene expression. We did a parallel group double-blind, placebo-controlled, 4-week trial to investigate this hypothesis. Thirteen morbidly obese women (25–52 years of age, body-mass index 48.0±4.0 kg/m2, range 41.1–57.6) were randomly assigned to EC (200/20 mg, n = 6) or to placebo (n = 7) administered three times a day orally, before undergoing bariatric surgery. All individuals had an energy-deficit diet equal to about 70% of resting metabolic rate (RMR) diet (mean 5769±1105 kJ/day). The RMR analysed by intention to treat and the UCP3 (long and short isoform) mRNA levels in rectus abdominis were the primary outcomes. Body weight, plasma levels of adrenaline, noradrenaline, triglycerides, free fatty acids, glycerol, TSH, fT4, and fT3 were assessed, as well as fasting glucose, insulin and HOMA index, at baseline and at the end of treatments. Body weight loss was evident in both groups when compared to baseline values (overall ？5.2±3.2%, p<0.0001) without significant differences between the treated groups. EC treatment increased the RMR (+9.2±6.8%, p = 0.020), differently from placebo which was linked to a reduction of RMR (？7.6±6.5%, p = 0.029). No significant differences were seen in other metabolic parameters. Notably, no changes of either UCP3 short or UCP3 long isoform mRNA levels were evident between EC and placebo group. Our study provides evidence that 4-week EC administration resulted in a pronounced thermogenic effect not related to muscle UCP3 gene expression and weight loss in morbidly obese females under controlled conditions. Trial Registration ClinicalTrials.gov NCT02048215
References
[1]
Astrup A (2000) Thermogenic drugs as a strategy for treatment of obesity. Endocrine 13: 207–12. doi: 10.1385/endo:13:2:207
[2]
Molnar D, Torok K, Erhardt E, Jeges S (2000) Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord 24: 1573–8. doi: 10.1038/sj.ijo.0801433
[3]
Miller DS, Stock MJ, Stuart JA (1974) The effect of caffeine and carnitine on oxygen consumption of fed and fasted subjects. Proc Nutr Soc 33: A28–9.
[4]
Acheson KJ, Zahorska-Markiewicz B, Pittet PH, Anantharman K, Jequier E (1980) Caffeine and coffee. Their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am J Clin Nutr 33: 989–97.
[5]
Brunton LL, Chabner BA, Knollmann BC (2011) Adrenergic agonists and antagonists. In Goodman & Gilman’s The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 12th edition.
[6]
Bellet S, Roman L, Decastro O, Kim KE, Kershbaum A (1969) Effect of coffee ingestion on catecholamine release. Metabolism 18: 288–91. doi: 10.1016/0026-0495(69)90049-3
[7]
Berkowitz BA, Spector S (1971) Effect of caffeine and theophylline on peripheral catecholamines. Eur J Pharmacol 13: 193–7. doi: 10.1016/0014-2999(71)90150-6
[8]
Klaus S, Casteilla L, Bouillaud F, Ricquier D (1991) The uncoupling protein UCP: a membraneous mitochondrial ion carrier exclusively expressed in brown adipose tissue. Int J Biochem 23: 791–801. doi: 10.1016/0020-711x(91)90062-r
[9]
Shabalina IG, Petrovic N, de Jong JM, Kalinovich AV, Cannon B, et al. (2013) UCP1 in Brite/Beige Adipose Tissue Mitochondria Is Functionally Thermogenic. Cell Rep 5: 1196–203. doi: 10.1016/j.celrep.2013.10.044
[10]
Frontini A, Cinti S (2010) Distribution and development of brown adipocytes in the murine and human adipose organ. Cell Metab 11: 253–6. doi: 10.1016/j.cmet.2010.03.004
[11]
Enerb？ck S (2010) Human brown adipose tissue. Cell Metab 11: 248–52. doi: 10.1016/j.cmet.2010.03.008
[12]
Brand MD, Esteves TC (2005) Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab 2: 85–93. doi: 10.1016/j.cmet.2005.06.002
[13]
Gimeno RE, Dembski M, Weng X, Deng N, Shyjan AW, et al. (1997) Cloning and characterization of an uncoupling protein homolog: a potential molecular mediator of human thermogenesis. Diabetes 46: 900–906. doi: 10.2337/diab.46.5.900
[14]
Solanes G, Vidal-Puig A, Grujic D, Flier JS, Lowell BB (1997) The human uncoupling protein-3 gene. J Biol Chem 272: 25433–25436. doi: 10.1074/jbc.272.41.25433
[15]
Nabben M, Shabalina IG, Moonen-Kornips E, van Beurden D, Cannon B, et al. (2011) Uncoupled respiration, ROS production, acute lipotoxicity and oxidative damage in isolated skeletal muscle mitochondria from UCP3-ablated mice. Biochim Biophys Acta 1807: 1095–105. doi: 10.1016/j.bbabio.2011.04.003
[16]
Clapham JC, Arch JR, Chapman H, Haynes A, Lister C, et al. (2000) Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 406: 415–8. doi: 10.1038/35019082
[17]
Millet L, Vidal H, Andreelli F, Larrouy D, Riou JP, et al. (1997) Increased uncoupling protein-2 and ？3 mRNA expression during fasting in obese and lean humans. J Clin Invest 100: 2665–70. doi: 10.1172/jci119811
[18]
Kogure A, Sakane N, Takakura Y, Umekawa T, Yoshioka K, et al. (2002) Effects of caffeine on the uncoupling protein family in obese yellow kk mice. Clin Exper Pharm Phys 29: 391–394. doi: 10.1046/j.1440-1681.2002.03675.x
[19]
Clinical Trial Registry. Wikipedia website. Available: #http://en.wikipedia.org/wiki/Clinical_tr？ials_registry#cite_note-2. Accessed: 16 May 2014.
[20]
Astrup A, Buemann B, Christensen NJ, Toubro S, Thorbek G, et al. (1992) The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 41: 686–8. doi: 10.1016/0026-0495(92)90304-s
[21]
Ramsey JJ, Colman RJ, Swick AG, Kemnitz JW (1998) Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine. Am J Clin Nutr 68: 42–51.
[22]
Forster CD, Macdonald IA (1999) The assay of the catecholamine content of small volumes of human plasma. Biomed Chromatogr 13: 209–215. doi: 10.1002/(sici)1099-0801(199905)13:3<209::aid-bmc820>3.0.co;2-z
[23]
Langin D, Dicker A, Tavernier G, Hoffstedt J, Mairal A, et al. (2005) Adipocyte lipases and defect of lipolysis in human obesity. Diabetes 54: 3190–7. doi: 10.2337/diabetes.54.11.3190
[24]
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistence and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28: 412–419. doi: 10.1007/bf00280883
[25]
Weir JB (1949) New methods for calculating metabolic rate with special reference to protein. J Physiol 109: 1–49.
[26]
Astrup A, Breum L, Toubro S, Hein P, Quaade F (1992) The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes Relat Metab Disord 16: 269–277.
[27]
Pasquali R (1993) Casimirri (1993) Clinical aspects of ephedrine in the treatment of obesity. Int J Obes Relat Metab Disord 17: S65–S68.
[28]
Ingerslev J, Svendsen TL, Mork A (1997) Is an ephedrine-caffeine treatment contraindicated in hypertension? Int J Obes Relat Metab Disord 21: 666–673. doi: 10.1038/sj.ijo.0800457
[29]
Buemann B, Marckmann P, Christensen NJ, Astrup A (1994) The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet. Int J Obes Relat Metab Disord 18: 329–332.
[30]
Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, et al. (1999) Pharmaceutical cost savings of treating obesity with weight loss medication. Obes Res 716: 523–530. doi: 10.1002/j.1550-8528.1999.tb00709.x
[31]
Krieger DR, Daly PA, Dulloo AG, Ransil BJ, Young JB, et al. (1990) Caffeine and aspirin promote weight loss in obese subjects. Trans Assoc Am Physicians 103: 307–312.
[32]
Hallas J, Bjerrum L, St？vring H, Andersen M (2008) Use of a Prescribed Ephedrine/Caffeine Combination and the Risk of Serious Cardiovascular Events: A Registry-based Case-Crossover Study. Am J Epidemiol 168: 966–973. doi: 10.1093/aje/kwn191
[33]
Liu AG, Smith SR, Fujioka K, Greenway FL (2013) The effect of leptin, caffeine/ephedrine, and their combination upon visceral fat mass and weight loss. Obesity (Silver Spring) 21: 1991–6. doi: 10.1002/oby.20416
[34]
Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, et al. (2003) Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 289: 1537–45. doi: 10.1001/jama.289.12.1470
[35]
Tseng YH, Cypess AM, Kahn CR (2010) Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov 9: 465–82. doi: 10.1038/nrd3138
[36]
Nedergaard J, Bengtsson T, Cannon B (2007) Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 293: E444–52. doi: 10.1152/ajpendo.00691.2006
[37]
Giralt M, Villarroya F (2013) White, brown, beige/brite: different adipose cells for different functions? Endocrinology 154: 2992–3000. doi: 10.1210/en.2013-1403
[38]
Nedergaard J, Cannon B (2013) UCP1 mRNA does not produce heat. Biochim Biophys Acta 2013 1831: 943–9. doi: 10.1016/j.bbalip.2013.01.009
[39]
Bukowiecki L, Jahjah L, Follea N (1982) Ephedrine, a potential slimming drug, directly stimulates thermogenesis in brown adipocytes via beta-adrenoreceptors. Int J Obes 6: 343–350.
[40]
Dulloo AG (1993) Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 17: S35–S40.
[41]
Dulloo AG, Seydoux J, Girardier L (1992) Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism 41: 1233–41. doi: 10.1016/0026-0495(92)90015-3
[42]
Diepvens K, Westerterp KR, Westerterp-Plantenga MS (2007) Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. Am J Physiol Regul Integr Comp Physiol 292: R77–85. doi: 10.1152/ajpregu.00832.2005
[43]
De Matteis R, Arch JR, Petroni ML, Ferrari D, Cinti S, et al. (2002) Immunohistochemical identification of the β3-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine. Int J Obes Relat Metab Disord 26: 1442–50. doi: 10.1038/sj.ijo.0802148
[44]
Casazza K, Allison DB (2012) Stagnation in the clinical, community and public health domain of obesity: the need for probative research. Clinical Obesity 2: 83–85. doi: 10.1111/j.1758-8111.2012.00052.x
